- Home
- SILC vs MDXH Comparison
SILC vs MDXH Comparison
Compare SILC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- MDXH
- Stock Information
- Founded
- SILC 1987
- MDXH 2003
- Country
- SILC Israel
- MDXH Belgium
- Employees
- SILC N/A
- MDXH N/A
- Industry
- SILC Computer Manufacturing
- MDXH
- Sector
- SILC Technology
- MDXH
- Exchange
- SILC Nasdaq
- MDXH Nasdaq
- Market Cap
- SILC 91.4M
- MDXH 73.3M
- IPO Year
- SILC 1994
- MDXH 2021
- Fundamental
- Price
- SILC $14.62
- MDXH $1.50
- Analyst Decision
- SILC Hold
- MDXH Buy
- Analyst Count
- SILC 2
- MDXH 1
- Target Price
- SILC N/A
- MDXH $6.00
- AVG Volume (30 Days)
- SILC 26.0K
- MDXH 86.9K
- Earning Date
- SILC 04-28-2025
- MDXH 04-30-2025
- Dividend Yield
- SILC N/A
- MDXH N/A
- EPS Growth
- SILC N/A
- MDXH N/A
- EPS
- SILC N/A
- MDXH N/A
- Revenue
- SILC $58,114,000.00
- MDXH $90,049,000.00
- Revenue This Year
- SILC $6.22
- MDXH $23.38
- Revenue Next Year
- SILC $19.10
- MDXH $16.84
- P/E Ratio
- SILC N/A
- MDXH N/A
- Revenue Growth
- SILC N/A
- MDXH 28.29
- 52 Week Low
- SILC $11.35
- MDXH $1.35
- 52 Week High
- SILC $18.24
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- SILC 40.21
- MDXH 41.36
- Support Level
- SILC $14.21
- MDXH $1.40
- Resistance Level
- SILC $15.37
- MDXH $1.66
- Average True Range (ATR)
- SILC 0.65
- MDXH 0.08
- MACD
- SILC 0.03
- MDXH 0.00
- Stochastic Oscillator
- SILC 27.70
- MDXH 36.76
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.